Metabolic Syndrome May Up Risk for VTE Recurrence After DVT
Significantly higher odds seen for all four components of MetS, with largest risk increase for hyperlipidemia
Significantly higher odds seen for all four components of MetS, with largest risk increase for hyperlipidemia
A review and meta-analysis of 25 randomized controlled trials showed that single-agent treatment strategies were generally more effective than combination strategies.
Continuing warfarin therapy for 18 months after an initial 6-month course decreased incidence of venous thrombosis and major bleeding.
Patients with severe sickle cell disease were more than twice as likely to experience recurrent thromboembolism compared with patients with less severe disease.
The neural network developed in this study yielded a false-negative rate of 0.22%.
An analysis of 2300 patients found similar prevalence of abdominal, pelvic, and thoracic cancer in patients with deep vein thrombosis and pulmonary embolism.
Patients receiving rivaroxaban did not experience a statistically significant decrease in thrombotic events compared with patients receiving placebo.
Thromboprophylactic treatment and serum albumin levels were not found to be associated with deep vein thrombosis incidence.
Researchers conducted a systematic literature review to characterize the complications experienced by patients with upper extremity deep vein thrombosis.
No differences were observed in patency rates or incidence of post-thrombotic syndrome in patients treated with rivaroxaban or a vitamin K antagonist.